Soligenix: Advancing Rare Disease Treatments and Fighting Emerging Diseases
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.
-
48:58
RedChip
10 months agoSoligenix: Illuminating the Future of Rare Disease Therapies
5 -
12:00
RedChip
1 year agoSoligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity
2 -
2:04
Real Truth Real News
1 year ago💥 HUGE! Hydroxychloroquine Allows Viruses to Attack Cancer Cells While Leaving Healthy Cells, Healthy....
7.31K20 -
2:04
iamthe1
1 year agoHydroxychloroquine Kills Cancer Cells
18 -
4:13
The Igonrant Entrepreneur
10 months agoThe First AI-Generated Drug Enters Human Trials, Pioneering a New Era in Medicine!
22 -
3:35
Atomic Analyzer
6 months agoCRISPR Milestone: UK Approves the Revolutionary Treatment for Genetic Diseases
571 -
1:13
Waking the World up
3 months agoShemane Nugent with David Schmidt - mRNA Post Jab Study – Mutation in WBC's - “Horns and a Tail”
1.69K -
2:09
Fear Not Experience News Network
1 year agoHQ Allows Cancer Cells To Be Attacked, While Protecting Healthy Cells
79 -
1:06:09
Cancer - Non-Chemo options
2 months agoTreating Cancer - Dr Thomas Seyfried
51 -
2:38
Asher Press
1 year agoPfizer CEO Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
170